To determine the immunogenicity and antitumor activity of a vaccine consisting of autologous, tumor-derived heat shock protein gp96-peptide complexes (HSPPC-96, Oncophage; Antigenics, Inc, Woburn, MA) in metastatic (American Joint Committee on Cancer stage IV) melanoma patients.
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings / F. Belli, A. Testori, L. Rivoltini, M. Maio, G. Andreola, M. R. Sertoli, G. Gallino, A. Piris, A. Cattelan, I. Lazzari, M. Carrabba, G. Scita, C. Santantonio, L. Pilla, G. Tragni, C. Lombardo, F. Arienti, A. Marchianò, P. Queirolo, F. Bertolini, A. Cova, E. Lamaj, L. Ascani, R. Camerini, M. Corsi, N. Cascinelli, J. J. Lewis, P. Srivastava, G. Parmiani. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 20:20(2002 Oct 15), pp. 4169-80-4180.
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings
G. Scita;M. Corsi;
2002
Abstract
To determine the immunogenicity and antitumor activity of a vaccine consisting of autologous, tumor-derived heat shock protein gp96-peptide complexes (HSPPC-96, Oncophage; Antigenics, Inc, Woburn, MA) in metastatic (American Joint Committee on Cancer stage IV) melanoma patients.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.